The acceleration of ALTO-207 into an additional Phase 3 monotherapy trial is a clear positive catalyst, reflecting management's confidence in the program. Key milestones to watch: ALTO-207 Phase 2b topline data in 2H 2027 and Phase 3 initiation in early 2027. The strong cash position reduces near-term dilution risk.
Price Chart
Executive Summary
Alto Neuroscience disclosed a preliminary cash balance of ~$244.2M as of June 30, 2026 (down from $264.2M at Q1 end) and announced plans to accelerate and expand ALTO-207 development, including an additional Phase 3 monotherapy trial in treatment-resistant depression. The strong cash runway through 2029 supports this expanded pipeline, signaling management confidence in ALTO-207's potential.
Key Facts
- Preliminary cash, cash equivalents, and restricted cash of approximately $244.2 million as of June 30, 2026.
- Company intends to accelerate and expand ALTO-207 clinical development, including an additional planned Phase 3 trial as monotherapy for treatment-resistant depression.
- Cash runway expected to fund planned operations through 2029, including ALTO-207 Phase 2b/3 trials and potential NDA submission.
Financial Impact
Cash balance of $244.2M provides approximately 2-3 years of runway at current burn rate (~$27M/quarter in Q1 2026). Expanded development may increase R&D spend but is funded.
Risk Factors
- Clinical trial failure or disappointing data for ALTO-207 could significantly impair the stock.
- Preliminary cash balance is unaudited and may change upon completion of Q2 2026 accounting procedures.
- Expanded development may increase cash burn, potentially requiring future financing if timelines extend.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082875 |
| Document: 0001104659-26-082875-index-headers.html | 0001104659-26-082875 |
| Document: 0001104659-26-082875-index.html | 0001104659-26-082875 |
| Document: 0001104659-26-082875.txt | 0001104659-26-082875 |
| 8-K Data (Synthetic) | 0001104659-26-082875 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | Institutional Cluster | $32.30 $34.25 | ▲ +6.04% | ▲ +8.00% | $22.11 (−31.55%) |
Jul 14, 2026 14w ago | 8-K | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $22.11 (+20.47%) |
Jul 14, 2026 14w ago | 424B5 | $27.80 $25.90 | ▲ +6.83% | ▲ +5.54% | $22.11 (+20.47%) |
Jul 13, 2026 15w ago | 8-K | $28.03 $27.54 | ▼ −1.75% | ▼ −0.96% | $22.11 (−21.12%) |
Jun 11, 2026 19w ago | Institutional Cluster | $21.47 $22.74 | ▲ +5.92% | ▲ +5.24% | $22.11 (+2.98%) |
May 29, 2026 21w ago | 3 | $19.80 $18.26 | ▼ −7.78% | ▼ −5.03% | $22.11 (+11.67%) |
May 28, 2026 21w ago | 8-K | $20.22 $18.85 | ▼ −6.78% | ▼ −6.73% | $22.11 (+9.35%) |
May 13, 2026 23w ago | 8-K | $22.85 $20.45 | ▼ −10.50% | ▼ −9.35% | $22.11 (−3.24%) |
Apr 21, 2026 26w ago | EFFECT | $25.59 $24.47 | ▼ −4.38% | ▼ −5.46% | $22.11 (−13.60%) |
Apr 10, 2026 28w ago | S-3 | $25.75 $27.33 | ▲ +6.14% | ▲ +2.84% | $22.11 (−14.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers